ITGB1: A Protein Role in Cell Adhesion, Migration and Angiogenesis

Target Name: ITGB1

NCBI ID: G3688

ITGB1

ITGB1: A Protein Role in Cell Adhesion, Migration and Angiogenesis

ITGB1, also known as integrin alpha-2 (CD29), is a protein that plays a crucial role in the formation and maintenance of blood vessels. It is a transmembrane protein that is composed of three constant and one variable region. The constant regions contain the extracellular domain, the transmembrane domain, and the intracellular domain. The variable region contains the alpha-2 subunit, which consists of two heavy chains and two light chains.

ITGB1 is a protein that is expressed in various tissues throughout the body, including the heart, the kidneys, the liver, and the intestine. It is involved in the regulation of cell adhesion, migration, and angiogenesis. ITGB1 has been implicated in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

One of the most promising aspects of ITGB1 is its potential as a drug target. The ITGB1 gene has been validated as a potential therapeutic target in various preclinical studies. For example, researchers have shown that inhibiting ITGB1 can lead to the regression of human cancer xenografts. Additionally, ITGB1 has been shown to be involved in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Therefore, targeting ITGB1 with small molecules or antibodies has the potential to provide new treatments for these diseases.

In addition to its potential as a drug target, ITGB1 also has the potential as a biomarker. The ITGB1 protein is a component of the intercellular adhesion molecule (ICAM), which is a complex that is involved in the regulation of cell-cell adhesion. Therefore, the level of ITGB1 in cell samples can be used as a measure of the level of ICAM. This can be useful for the diagnosis and monitoring of various diseases, including cancer and neurodegenerative diseases.

Another promising aspect of ITGB1 is its role in the regulation of angiogenesis. Angiogenesis is the process by which new blood vessels are formed during wound healing and tissue repair. ITGB1 is involved in the regulation of angiogenesis by promoting the migration of progenitor cells to the site of an injury or infection. This can lead to the formation of new blood vessels and the delivery of oxygen and nutrients to the injured or infected tissue.

In conclusion, ITGB1 is a protein that plays a crucial role in the regulation of cell adhesion, migration, and angiogenesis. Its potential as a drug target and biomarker make it an attractive target for the development of new treatments for various diseases. Further research is needed to fully understand the role of ITGB1 in the regulation of angiogenesis and the development of various diseases.

Protein Name: Integrin Subunit Beta 1

Functions: Integrins alpha-1/beta-1, alpha-2/beta-1, alpha-10/beta-1 and alpha-11/beta-1 are receptors for collagen. Integrins alpha-1/beta-1 and alpha-2/beta-2 recognize the proline-hydroxylated sequence G-F-P-G-E-R in collagen. Integrins alpha-2/beta-1, alpha-3/beta-1, alpha-4/beta-1, alpha-5/beta-1, alpha-8/beta-1, alpha-10/beta-1, alpha-11/beta-1 and alpha-V/beta-1 are receptors for fibronectin. Alpha-4/beta-1 recognizes one or more domains within the alternatively spliced CS-1 and CS-5 regions of fibronectin. Integrin alpha-5/beta-1 is a receptor for fibrinogen. Integrin alpha-1/beta-1, alpha-2/beta-1, alpha-6/beta-1 and alpha-7/beta-1 are receptors for lamimin. Integrin alpha-6/beta-1 (ITGA6:ITGB1) is present in oocytes and is involved in sperm-egg fusion (By similarity). Integrin alpha-4/beta-1 is a receptor for VCAM1. It recognizes the sequence Q-I-D-S in VCAM1. Integrin alpha-9/beta-1 is a receptor for VCAM1, cytotactin and osteopontin. It recognizes the sequence A-E-I-D-G-I-E-L in cytotactin. Integrin alpha-3/beta-1 is a receptor for epiligrin, thrombospondin and CSPG4. Alpha-3/beta-1 may mediate with LGALS3 the stimulation by CSPG4 of endothelial cells migration. Integrin alpha-V/beta-1 is a receptor for vitronectin. Beta-1 integrins recognize the sequence R-G-D in a wide array of ligands. When associated with alpha-7 integrin, regulates cell adhesion and laminin matrix deposition. Involved in promoting endothelial cell motility and angiogenesis. Involved in osteoblast compaction through the fibronectin fibrillogenesis cell-mediated matrix assembly process and the formation of mineralized bone nodules. May be involved in up-regulation of the activity of kinases such as PKC via binding to KRT1. Together with KRT1 and RACK1, serves as a platform for SRC activation or inactivation. Plays a mechanistic adhesive role during telophase, required for the successful completion of cytokinesis. Integrin alpha-3/beta-1 provides a docking site for FAP (seprase) at invadopodia plasma membranes in a collagen-dependent manner and hence may participate in the adhesion, formation of invadopodia and matrix degradation processes, promoting cell invasion. ITGA4:ITGB1 binds to fractalkine (CX3CL1) and may act as its coreceptor in CX3CR1-dependent fractalkine signaling (PubMed:23125415, PubMed:24789099). ITGA4:ITGB1 and ITGA5:ITGB1 bind to PLA2G2A via a site (site 2) which is distinct from the classical ligand-binding site (site 1) and this induces integrin conformational changes and enhanced ligand binding to site 1 (PubMed:18635536, PubMed:25398877). ITGA5:ITGB1 acts as a receptor for fibrillin-1 (FBN1) and mediates R-G-D-dependent cell adhesion to FBN1 (PubMed:12807887, PubMed:17158881). ITGA5:ITGB1 is a receptor for IL1B and binding is essential for IL1B signaling (PubMed:29030430). ITGA5:ITGB3 is a receptor for soluble CD40LG and is required for CD40/CD40LG signaling (PubMed:31331973). Plays an important role in myoblast differentiation and fusion during skeletal myogenesis (By similarity)

The "ITGB1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ITGB1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets